Market capitalization | $17.90b |
Enterprise Value | $20.78b |
P/E (TTM) P/E ratio | 24.14 |
EV/FCF (TTM) EV/FCF | 16.92 |
EV/Sales (TTM) EV/Sales | 2.50 |
P/S ratio (TTM) P/S ratio | 2.15 |
P/B ratio (TTM) P/B ratio | 1.83 |
Revenue growth (TTM) Revenue growth | 3.63% |
Revenue (TTM) Revenue | $8.31b |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
19 Analysts have issued a ICON Plc forecast:
19 Analysts have issued a ICON Plc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 8,307 8,307 |
4%
4%
|
|
Gross Profit | 1,916 1,916 |
7%
7%
|
|
EBITDA | 1,722 1,722 |
7%
7%
|
EBIT (Operating Income) EBIT | 1,143 1,143 |
16%
16%
|
Net Profit | 748 748 |
46%
46%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.
Head office | Ireland |
CEO | Stephen Cutler |
Employees | 41,100 |
Founded | 1989 |
Website | www.iconplc.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.